LUPIN LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,655 INR | +0.46% |
|
+3.78% | +25.11% |
| Apr. 24 | Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility | MT |
| Apr. 22 | INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains | RE |
Presenter SpeechSunil Makharia (Executives)Good morning, shareholders. Hope you all are doing ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-05-05
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
1,655
INR
Average target price
1,516
INR
Spread / Average Target
-8.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.11% | 9B | |
| +26.08% | 681B | |
| +21.85% | 556B | |
| -4.77% | 361B | |
| +16.97% | 325B | |
| +5.69% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.40% | 157B |
- Stock Market
- Equities
- LUPIN Stock
- News Lupin Limited
- Transcript : Lupin Limited - Shareholder/Analyst Call
